* Circio presented an extensive circVec data package in an oral and a poster
  presentation at the ASGCT 2026 Annual Meeting
* The warrant program exercise period between 26 May -- 9 June offers the
  opportunity for warrant holders to subscribe for Circio shares at a discount
  to the VWAP from the warrant pricing period
* CEO Dr. Erik D Wiklund will summarize the ASGCT presentation, provide an
  overview of the warrant process and planned use of proceeds for the warrant
  funds received

Oslo, Norway, 22 May 2026 -- Circio Holding ASA (OSE: CRNA), a biotechnology
company developing novel circular RNA expression technology for gene and cell
therapy, invites to a live webcast in Norwegian at 10:00am CET on Thursday 28
May 2026.

In the webcast, CEO Dr. Erik D Wiklund will summarize the recent oral and
poster presentations given at the ASGCT Annual Meeting in Boston 11-15 May
2026 where Circio presented an extensive data package showcasing the latest
data package on its circVec circular RNA technology platform. The webcast will
also include practical information and timelines relating to the warrant
program with exercise period from 26 May to 9 June, including the planned use
of proceeds for warrant funds received.

The webcast will be held in Norwegian. Questions can be submitted in advance
by email to Erik D Wiklund: erik.wiklund@circio.com or directly in the live
webcast.

Time: 10:00 CET on Thursday 28 May 2026

Click here to access Teams webcast
(https://teams.microsoft.com/meet/332542909160846?p=A6gvhzCTeBuLqLxpH3)
Meeting ID: 332 542 909 160 846
Passcode: kH6xK9CP

A recording of the webcast will be made available on the Circio webpage
(http://www.circio.com/)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Neil Hunter -- Hunter PR
Phone: +44 782 125 5568
Email: neiljameshunter@gmail.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 50-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

This stock exchange announcement was published by Mats Hermansen, VP Finance,
on behalf of the Company, at the time and date stated above in this
announcement.
on behalf of the Company\, at the time and date stated above in this\
announcement.\